Pfizer Japan spin-out RaQualia inks new R&D, licensing deals
This article was originally published in Scrip
RaQualia Pharma, a drug development venture spun out from Pfizer's R&D operations in Japan, has taken further steps towards securing new revenue streams with the signing of research and licensing deals with Lilly and Durata Therapeutics.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.